Once A Year Osteoporosis Drug Reclast Gets FDA Approval

 

Swiss drug maker Novartis announced that Reclast (zoledronic acid) has received approval from the US Food and Drug Administration (FDA) as a once a year treatment for women with osteoporosis. Osteoporosis (literally means "porous bones") occurs when bone mineral density (BMD) falls and the physical and chemical structure inside bones is disrupted leading to skeletal fragility and bones that fracture easily (it is sometimes called brittle bone disease).

Once A Year Osteoporosis Drug Reclast Gets FDA Approval